ABSTRACT
Vigorous non-pharmaceutical interventions have largely suppressed the COVID-19 outbreak in Wuhan, China. We developed a susceptible-exposed-infectious-recovered model to study the transmission dynamics and evaluate the impact of interventions using 32,583 laboratory-confirmed cases from December 8, 2019 till March 8, 2020, accounting for time-varying ascertainment rates, transmission rates, and population movements. The effective reproductive number R0 dropped from 3.89 (95% credible interval: 3.79-4.00) before intervention to 0.14 (0.11-0.28) after full-scale multi-8 pronged interventions. By projection, the interventions reduced the total infections in Wuhan by 96.5% till March 8. Furthermore, we estimated that 79% (lower bound: 60%) of the total infections were unascertained, potentially including asymptomatic and mild-symptomatic cases. The probability of resurgence was 0.22 and 0.10 based on models with 79% and 60% infections unascertained, respectively, assuming interventions were lifted after a 14-day period of no new ascertained infections. These results provide important implications for continuing surveillance and interventions to eventually contain the outbreak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partly supported by the Fundamental Research Funds for the Central Universities (2019kfyXMBZ015), the 111 Project (X.H., S.C., D.W., C.W., T.W.). X.L. is supported by Harvard University.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Co-first authors.
Disclaimer: An early version of this manuscript was part of a preprint entitled “Evolving epidemiology and impact of non-pharmaceutical interventions on the outbreak of coronavirus disease 2019 in Wuhan, China”, which was posted on medRxiv on March 6, 2020. (https://www.medrxiv.org/content/10.1101/2020.03.03.20030593v1)
Data Availability
Data will be released once granted by the authorities.
